POWERFUL WORDS-
"I am thrilled to be joining Amarantus' Board of Directors, a company which I believe is poised for tremendous success in the years ahead," stated Dr. Rubinfeld. "With its robust portfolio approach to products in development, the opportunities for the company are extraordinary."
"MANF, which was discovered via Amarantus' proprietary protein discovery platform PhenoGuard, may become one of the most important medical advancements in the history of the biopharmaceutical industry to-date, and has a potentially accelerated regulatory pathway to market under the Orphan Drug Act," Dr. Rubinfeld continued. "PhenoGuard, itself, could become one of the most valuable drug discovery platforms in the industry by yielding a plethora of additional novel neurotrophic factors. Furthermore, the company's product candidate Eltoprazine, which is about to enter Phase 2b clinical testing, has the potential to be extremely important in addressing an ever-growing, unmet need in Parkinson's disease treatment."
"I am thrilled to be joining Amarantus' Board of Directors, a company which I believe is poised for tremendous success in the years ahead," stated Dr. Rubinfeld. "With its robust portfolio approach to products in development, the opportunities for the company are extraordinary."
"MANF, which was discovered via Amarantus' proprietary protein discovery platform PhenoGuard, may become one of the most important medical advancements in the history of the biopharmaceutical industry to-date, and has a potentially accelerated regulatory pathway to market under the Orphan Drug Act," Dr. Rubinfeld continued. "PhenoGuard, itself, could become one of the most valuable drug discovery platforms in the industry by yielding a plethora of additional novel neurotrophic factors. Furthermore, the company's product candidate Eltoprazine, which is about to enter Phase 2b clinical testing, has the potential to be extremely important in addressing an ever-growing, unmet need in Parkinson's disease treatment."
